Dose determination of VV116 in COVID-19 patients with severe liver dysfunction: a case report DOI Creative Commons
Liu Yang,

Wenwen Jiang,

Jianqing Deng

и другие.

Frontiers in Medicine, Год журнала: 2025, Номер 12

Опубликована: Фев. 25, 2025

VV116 is an oral antiviral drug against SARS-CoV-2, known for its favorable efficacy and safety profile. But application in patients with severe liver dysfunction has not been evaluated. Here, we report a case which patient aplastic anemia impairment (recovery phase of acute failure) was infected SARS-CoV-2. Based on clinical trials pharmacokinetic analysis about VV116, initiated reduced dose 300 mg every 12 h day 1, 200 days 2-5 therapy. Finally, the patient's viral load rapidly dropped to undetected level, no drug-related adverse effects were observed.

Язык: Английский

Dose determination of VV116 in COVID-19 patients with severe liver dysfunction: a case report DOI Creative Commons
Liu Yang,

Wenwen Jiang,

Jianqing Deng

и другие.

Frontiers in Medicine, Год журнала: 2025, Номер 12

Опубликована: Фев. 25, 2025

VV116 is an oral antiviral drug against SARS-CoV-2, known for its favorable efficacy and safety profile. But application in patients with severe liver dysfunction has not been evaluated. Here, we report a case which patient aplastic anemia impairment (recovery phase of acute failure) was infected SARS-CoV-2. Based on clinical trials pharmacokinetic analysis about VV116, initiated reduced dose 300 mg every 12 h day 1, 200 days 2-5 therapy. Finally, the patient's viral load rapidly dropped to undetected level, no drug-related adverse effects were observed.

Язык: Английский

Процитировано

1